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Wolfram syndrome is a rare disease caused by mutations in the WFS1 gene leading to symptoms in 
early to mid-childhood. Brain structural abnormalities are present even in young children, but it is not 
known when these abnormalities arise. such information is critical in determining optimal outcome 
measures for clinical trials and in understanding the aberrant neurobiological processes in Wolfram 







cerebellar cortex. these patterns suggest that there may be early, stalled white matter development 
in Wolfram syndrome, with additional degenerative processes in both white and gray matter. Ideally, 
animal models could be used to identify the underlying mechanisms and develop specific interventions.
Wolfram syndrome (OMIM #222300) is a rare (1 in 500,000 to 1,000,000) autosomal recessive genetic disease 
originally described as the combination of insulin dependent diabetes mellitus, optic nerve atrophy, diabetes 
insipidus and deafness1. Neurodegeneration and neurological features were thought to appear at later stages of the 
disease, ultimately leading to death in middle adulthood2. Since the major causative gene (WFS1)3 was identified 
in 1998, greater variability in the severity of the disease, the complexity of the phenotype and the rate of progres-
sion has been revealed. It is now evident that not all of the presumed core symptoms of Wolfram syndrome are 
present in all of the patients who are genetically identified4–6 and that neurologic abnormality is present even 
at early stages of the disease in some patients7–9. Rare neuropathological examinations of Wolfram syndrome 
patients’ brains have noted loss of neurons, myelin and myelinated axons10–14; however it is unclear when in the 
disease process these occur. Given that the neurological features of Wolfram syndrome are life-threatening and 
evolve over development, these aspects should be targets of intervention and thus require greater attention.
Mutations in the WFS1 gene predispose pancreatic β-cells to ER stress-mediated apoptosis15–22 and this mech-
anism may also account for central nervous system degeneration, including, perhaps, myelin degradation23. 
However, this idea has not been well tested in brain cells, nor do we understand how this mechanism interacts 
with neurodevelopmental processes. While molecular and cellular experiments have led the field closer to iden-
tifying potential interventions for degenerative processes in Wolfram syndrome, the identification of reliable 
neurological biomarkers and an understanding of underlying neuropathophysiology and clinical correlates is in 
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its infancy. For these reasons, determining the trajectory of structural brain changes in Wolfram syndrome during 
development is a critical step forward for the field.
In our previous cross-sectional neuroimaging study, individuals with Wolfram syndrome, as compared to age 
and sex equivalent controls, had reduced gray and white matter volumes primarily in the ventral pons, brainstem, 
cerebellum, and thalamus with altered white matter microstructural integrity in tracts such as optic radiations9,24. 
Interestingly, decreased brainstem and cerebellar volumes were seen in almost all individuals with Wolfram 
syndrome, regardless of age or duration of diabetes or other features of the disease. These data suggested that 
Wolfram syndrome affects the early development of specific brain regions. However, cross-sectional comparisons 
cannot determine whether these abnormalities evolve over time within an individual or at what rate, nor how 
they are distinguished from normal developmental trajectories. Thus, we have performed yearly neuroimaging 
studies in patients with Wolfram syndrome and controls over an age range of active neurodevelopment. By exam-
ining morphometric change with multiple spatial and statistical methods, we aim to converge on the regions 
and tissue types that are most affected in Wolfram syndrome, distinguish between earlier vs. later occurring 
abnormalities and identify rates of regional change that diverge from normal neurodevelopmental trajectories. 
Findings may indicate future targets for brain-specific intervention and identify outcome measures for clinical 
trials targeting neurological symptoms. It will also greatly expand our understanding of the longitudinal pheno-
type of WFS1-related disorders, rather than classically defined Wolfram syndrome. Such knowledge will have a 
significant impact on patients and families by allowing physicians to provide more accurate prognoses.
Methods
participants. This study was approved by the Human Research Protection Office at Washington University in 
St. Louis and all methods were conducted in accordance with relevant guidelines and regulations. Children under 
age 18 gave informed assent and parents/guardians gave informed, written consent. Participants 18 or older gave 
informed, written consent.
Wolfram syndrome group. Patients were recruited into the Washington University Wolfram Syndrome Research 
Clinic through self or physician referral or from the Washington University Wolfram Syndrome Registry. Patients 
had to have known WFS1 mutations, be under the age of 30 at enrollment and aware of their diagnosis, and be 
able to travel to St. Louis for annual research clinic visits. Patients were evaluated annually by physician spe-
cialists, answered questionnaires and performed different tests. Data from some of these measures have been 
previously reported5,7–9,25–34. Each patient was also assessed by a neurologist who performed the Wolfram Unified 
Rating Scale (WURS), a scale designed to measure the severity of symptoms commonly associated with Wolfram 
syndrome26. We used the physical subscale as a measure of neurologic symptom severity. Wolfram patients with-
out contraindications also underwent magnetic resonance imaging (MRI) at each visit.
Control group. Healthy individuals with and without type 1 diabetes mellitus composed the control group. 
Participants with type 1 diabetes were recruited from the Pediatric Diabetes Clinic at St. Louis Children’s Hospital 
and Washington University School of Medicine in St. Louis. They were excluded for diagnosed psychiatric disor-
der, significant neurological history not due to diabetes, known premature birth (<36 weeks gestation) with com-
plications, psychoactive medications, or physical limitations that would interfere with testing. No participants 
had known retinopathy, nephropathy or neuropathy at the time of testing. Non-diabetic individuals were either 
healthy siblings of the participants with diabetes or from the community. Non-diabetic controls were excluded 
for known current or past history of neurological and psychiatric diagnoses or other significant health conditions. 
Each participant in these control groups underwent MRI scans, answered questionnaires and completed cogni-
tive tests at each annual visit for up to 3 years.
Neuroimaging. Before beginning scanning, participants with diabetes were determined to always have blood 
glucose levels above 70 mg/dl, and below 300 mg/dl when possible. Scanning was performed on a single Siemens 
3T Tesla Tim Trio at Washington University and included T1 and T2-weighted sequences. The T1-weighted 
Magnetization-Prepared Rapid Gradient-Echo (MPRAGE) sequence had the following parameters: sagittal 
acquisition, repetition time (TR) = 2400 ms, echo time (TE) = 3.16 ms, inversion time (TI) = 1000 ms, voxel reso-
lution = 1 × 1 × 1 mm, time = 8:09 min. The T2-weighted sequence had the following parameters: sagittal acqui-
sition, TR = 3200 ms, TE = 455 ms, voxel resolution = 1 × 1 × 1 mm, time = 4:43 min. All imaging sessions with 
acceptable T1 and T2 scans were selected for analyses. Diffusion-weighted, limited field of view T2, and resting 
BOLD scans were also attempted, but data are not reported here.
Analysis methods were selected to provide complementary and convergent information on how gray and 
white matter volumes change over time in Wolfram syndrome and controls. We used a voxel-wise imaging anal-
ysis approach that disregarded anatomical boundaries and tissue types and a region of interest (ROI) method, 
independently analyzed with appropriate statistical models for varying numbers of time points across partici-
pants. Since previous analyses have not found differences between healthy and diabetic groups9,24, we pooled the 
control groups and included the presence of diabetes as a covariate in the model to simplify statistical analyses 
and to maximize power.
Voxel-wise analysis methods. For each participant with two or more time points, a T1 and a T2 from each time 
point was processed using the serial longitudinal registration toolbox in SPM 12 with default settings35. For each 
time point per participant, the T2 was co-registered to the corresponding T1 from that visit. The deformation 
maps from the T1 longitudinal registration were then used to sample the T1 and T2 for each time point onto 
the mid-point average T1 longitudinal registration space and make an all-time-point average for both the T1 
and T2. The all-time-point average T1 and T2 were used as inputs for SPM segment36. Using both the T1 and 
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T2 images in SPM segment can improve segmentation accuracy (https://www.fil.ion.ucl.ac.uk/spm/doc/manual.
pdf). The resulting gray and white matter tissue probability maps (TPMs) for each participant were used to create 
study-specific gray and white matter templates using SPM’s DARTEL37. These templates were used to align each 
subject’s gray and white matter TPMs to a common group template space. To achieve a better correspondence 
with the MNI152 VI asymmetric template (MNI152_VIa) (http://nist.mni.mcgill.ca/?page_id=714), we seg-
mented the MNI152_VIa T1 template image with SPM segment and used SPM DARTEL to compute a mapping 
between MNI152_VIa and the common group template created from our data. For each person, we then took 
their average gray and white matter TPMs and the Jacobian determinant maps for each time point and warped 
them into MNI152_VIa space using the composite warp from subject space to MNI152_Via space. Each Jacobian 
determinant map (tensor-based morphometry map, “TBM”) represents degree of expansion or contraction from 
a template (subject or group) at the voxel level. The group-average gray and white matter TPMs were used to 
create a mask for voxel-wise analyses.
The sandwich estimator toolbox (SwE, version 1.2.8 for SPM) was used to statistically analyze TBM’s38. 
The SwE toolbox optimizes the analysis of longitudinal neuroimaging data by accommodating datasets that 
are small, unbalanced, and have missing data. SwE applies a non-iterative, marginal model to the data which 
allows each group to have its own covariance matrix and prevents within-subject convergence problems inher-
ent in longitudinal designs. The main effect of group (Wolfram vs controls) was tested by using the TBMs for 
time-point-to-group-template, while controlling for estimate of total intracranial volume (eTIV39), age, sex, and 
diabetes. Annualized change in volume (defined as time in years from each time point to the mid-point for each 
TBM) was modelled as a fixed effect. The interactions of group by time by age and of group by time, as well as 
the main effect of time within each group were tested using the TBMs for time-point-to-midpoint-average while 
controlling for age, sex, and diabetes. The wild bootstrap (WB) component of the SwE toolbox was used to make 
non-parametric inferences about cluster level data using family-wise error (FWE) correction (http://hdl.handle.
net/2268/186284). A cluster-forming threshold of p = 0.001 was used for the 999 bootstrap permutations, and 
FWE-corrected cluster-level p values were considered significant at p < 0.05.
Regions of interest (ROI) methods. For all participants with a T1 from at least one time point, the semi-automatic 
segmentation program Freesurfer (v5.3) was used to extract global and regional gray and white matter volumes 
at each time point using the longitudinal processing stream24,40. Specific regional volumes were selected for anal-
ysis to match the location of major clusters on voxel-wise group by time interaction maps that survived FWE 
correction. Regional volumes were averaged across left and right hemispheres when appropriate and corrected 
for eTIV39. Volumes for ventral pons were measured by first aligning the Freesurfer brainstem ROIs for each 
participant across all time points and then averaging them. Manual segmentation was then performed on each 
individual’s average brainstem ROI using previously described methods24 before applying those segments back to 
each time point, and extracting eTIV-corrected volumes9,24.
Statistical analyses assumed a linear relationship between regional brain volumes and time and used a random 
slope model (mixed model) to predict average annual rate of change for each regional volume. This model allowed 
slopes (annual rate of change) to vary randomly between participants and fit a separate regression line for each 
participant. The three-way interaction between group, time and age at the first testing session and all the two-way 
interactions, as well as sex and diabetes effect, were considered in a full model. Backward selection method was 
used to remove the most non-significant factor, one at each step, in the order of three-way interaction, two-way 
interactions and main effects. Analyses were two-tailed with a significance level of 0.05 and performed with SAS 
9.4 (SAS Institute, Cary, NC).
Power analyses were performed on the region with the greatest degree of abnormal change within just the 
Wolfram group to determine the sample size necessary to detect a significant effect of intervention in a clinical 
trial. Simulations were conducted to determine the sample size required to achieve at least 80% power to detect 
a 50% or 60% reduction in mean annual rate of progression at significance level of 0.05. Analyses assumed that 
measurements would occur every six months during a 3-year clinical trial, and that sample sizes and mean vol-
umes at baseline were equal for the two Wolfram groups (treatment vs. placebo). Mean trajectories were simu-
lated using the random slope model, using a mean annual rate of progression for the placebo group estimated 
from the current Wolfram data. Simulations assumed random slope and homoscedastic error normally distrib-
uted with zero mean and variance estimated from the Wolfram group data. Empirical power was calculated from 
1000 simulated trials.
Results
participants. Wolfram syndrome group. Adequate T1 and T2 images were acquired on 29 patients with 
Wolfram syndrome seen annually between 1 and 7 times (mean follow-up = 3.64 years) (Table 1).
Control group. Adequate T1 and T2 images were acquired on 24 type 1 diabetics and 28 non-diabetic partici-
pants, annually between 1 and 3 times (mean follow-up = 2.0 years). The type 1 diabetes group had overall higher 
HbA1c than the Wolfram group (sessions 1–3, p < 0.022), however, these groups did not differ in blood glucose 
levels before or after scans (sessions 1–3, p > 0.23) or in diabetes duration (t(51) = −0.07, p = 0.95). Wolfram and 
control groups did not differ in age at their first visit (baseline age range 5–25 and 6–26, respectively; t(79) = 0.09, 
p = 0.93) or in sex distribution (χ2 (1, 81) = 0, p = 0.99). See Table 1 for demographics and Fig. 1 for a plot of all 
participant ages and number of sessions.
Neuroimaging. Voxel-wise results. To confirm our previous cross-sectional neuroimaging findings in 
Wolfram syndrome, we first examined the main effect of group on cluster-wise bootstrap-corrected FWE P 
images. We found that the Wolfram group had lower volumes in the brainstem, cerebellum and thalamus and 
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slightly higher volumes in restricted temporal lobe cortex compared to controls (Fig. 2a). These findings largely 
overlap with our previous cross-sectional results which used smaller sample sizes and different analytic meth-
ods9,24. The current analysis further revealed that the Wolfram group had lower volumes than controls in the 
cerebellar and cerebral peduncles and internal capsule.
No clusters from the group by time by age interaction survived cluster-wise FWE correction. Significant group 
by time interactions were found within the brainstem, notably in the ventral pons, posterior thalamus, internal 
capsule, optic radiations, a small portion of the visual cortex, most of cerebellar white matter, a portion of cere-
bellar gray matter, cerebellar peduncles, and cerebral peduncles (Fig. 2b). In order to better understand the nature 













Sex M/F 15/14 27/25 13/15 14/10
Age (years)
Mean ± SD 13.8 ± 5.5 13.9 ± 5.0 14.1 ± 5.3 13.6 ± 4.7
Range 5.9–25.8 6.0–26.2 6.0–26.1 7.6–26.2
*Follow-up period 
(years)
Mean ± SD 3.6 ± 1.7 2.0 ± 0.3 1.9 ± 0.3 2.0 ± 0.2
Range 1.0–5.9 1.0–2.3 1.0–2.3 1.1–2.3
Diabetes duration 
(years)
Mean ± SD 7.9 ± 5.2 — — 7.8 ± 4.8
Range 0.4–16.6 — — 0.1–16.7
Diabetes mellitus Prevalence 29/29 — — —
    Age at dx (years)
Mean ± SD 5.9 ± 3.0 — — —
Range 2.7–13.9 — — —
Diabetes insipidus Prevalence 18/29 — — —
    Age at dx (years)
Mean ± SD 11.0 ± 3.8 — — —
Range 5.5–17.0 — — —
Hearing loss Prevalence 20/29 — — —
    Age at dx (years)
Mean ± SD 10.5 ± 4.7 — — —
Range 6.0–25.8 — — —
Optic nerve atrophy Prevalence 28/29 — — —
    Age at dx (years)
Mean ± SD 10.1 ± 3.9 — — —
Range 3.8–18.0 — — —
Table 1. Mean and standard deviation (SD) of demographic and clinical variables across Wolfram and control 
groups at session 1. There were no differences between the Wolfram and control groups for age (p = 0.93) or 
sex (p = 0.99), and there were no differences between Wolfram and the diabetic control groups for duration of 
diabetes (p = 0.95) at session 1. *Excludes participants with a single time point (Wolfram, n = 4; Non-diabetic 
control = 6; diabetic control = 6). Abbreviations: M, male; F, female; dx, diagnosis.
Figure 1. Ages of the 81 participants at each of their MRI scans. Each row on the Y-axis indicates an individual 
participant and symbols (connected by a line) indicate the participant’s age at each session (X-axis). Wolfram 
participants are shown in red and controls are shown in blue.
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indicate that within controls, as expected based on the literature, volumes increased across most major white mat-
ter regions, including brainstem and cerebellar white matter, whereas cortical gray matter volume decreased over 
time, particularly within the precuneus/cuneus and prefrontal cortex (Fig. 2c). In contrast, within the Wolfram 
group, white matter volumes did not show any increase over time. In addition, the ventral pons region of the 
brainstem and cerebellar white matter actually decreased in volume over time (Fig. 2d). Thalamus and cerebellar 
gray matter volume decreased in Wolfram over time, but was stable in controls.
Regions of interest (ROI) results. Based on the voxel-wise group by time findings, we selected brainstem, ventral 
pons, thalamus, cerebellar gray and cerebellar white matter regions. As expected, these regions all had significant 
interactions between group and time (p < 0.01; Table 2) and none had any group by time by age interactions, 
recapitulating the patterns observed in the voxel-wise analyses. In brainstem, ventral pons and cerebellar white 
matter, controls tend to increase in volume over time and age and the Wolfram group tend to decrease in volume 
over time and age (Fig. 3a–c). In the thalamus, we observed a striking decrease in volume in the Wolfram group 
over time while controls remained stable (Fig. 3e). Cerebellar gray matter decreased in both groups, but was more 
accentuated in the Wolfram group (Fig. 3d).
Figure 2. Clusters surviving FWE correction in each voxel-wise analysis at FWE p < 0.05. (a) Main effect of group: 
The Wolfram group has lower volume (yellow clusters) in multiple regions (e.g. brainstem, cerebellum, thalamus) 
and greater volume (blue) in relatively small portions of cortex compared to the control group. (b) Group × time 
interaction: Clusters where groups differed over time in volume (green) largely fell within the regions where the 
Wolfram group had lower volume than controls (yellow in a). (c) Main effect of time within the control group: 
Volume increased in most white matter regions (yellow and red clusters) and decreased in cortical gray matter 
regions (turquoise and blue) over time, as expected. (d) Main effect of time within the Wolfram group: Volume 
decreased over time (turquoise) in many white and gray matter regions, and no increased volume was seen 
anywhere in the brain. Expansion = increase in volume over time; Contraction = decrease in volume over time.
Brain Region
Wolfram (n = 29) Controls (n = 52)
Group × Time 
Interaction
Main Effect of 
Time: Wolfram
Mean ±SEM Mean ±SEM F p F p
Brainstem −123.61 26.08 182.39 17.71 70.03 <0.001 8.71 0.006
Ventral Pons −48.44 18.33 93.23 12.34 31.69 <0.001 2.62 0.117
Cerebellar White 24.32 26.24 248.91 18.02 32.52 <0.001 1.49 0.232
Cerebellar Gray −420.95 82.49 −49.26 60.43 6.83 0.01 13.42 0.001
Thalamus −84.68 5.86 11.26 4.81 34.60 <0.001 49.47 <0.001
Table 2. Mixed model results for regions of interest. Mean and standard error of the mean (SEM) of the 
estimated annual rates of change are shown for each region and group. F and p values for each region come from 
the interaction of group by time, controlling for age, sex, and diabetes, and the main effect of time within the 
Wolfram group, controlling for age and sex. Significant results at the p ≤ 0.01 level are in bold.
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Based on random slope models, the rate of change in each brain region was calculated for each person. As 
expected based on the group by time interactions from the mixed models, the average rate of change was sig-
nificantly different between the two groups for all regions (p < 0.001). In addition, within the control group, 
average rate of change was different from 0 (p < 0.03) for each region except for cerebellar gray matter. Within 
the Wolfram group, the average rate of change was different from 0 (p < 0.02) for all regions except for cerebellar 
white matter (Fig. 4). To explore how degree of symptom severity at entry to the study predicted change over 
time, we performed Spearman’s correlations between annual rate of change variables and the WURS Physical 
Scale Score (n = 5 correlations). The correlation between thalamic rate of change and WURS Physical survived 
Bonferroni correction (criterion p value 0.05/5 = 0.01; rs = −0.669, p = 0.003, n = 17; Fig. 5).
Within group mixed model analyses for the main effect of time within the Wolfram group determined that the 
largest effect was in the thalamus (F1,28 = 49.47, p < 0.0001; Table 2). Power analyses on the estimated annual rate 
of change in thalamus estimated that it would require 34 or 48 patients per study arm (treatment vs placebo) to 
detect a 60% or 50% slowing of the rate of volume loss due to an intervention.
Discussion
Our longitudinal morphometric neuroimaging study of Wolfram syndrome identified the brain regions and tis-
sue types that follow abnormal trajectories across development in this disease. Wolfram syndrome appears to be 
associated with deficient and stalled white matter growth and abnormal loss of white and gray matter in specific 
regions over time. The patterns observed suggest that there may be different mechanisms underlying the brain 
abnormalities present early in disease (hypo- and stalled myelination) vs. the evolution of abnormalities across 
Figure 3. Volumes of regions of interests (corrected for eTIV) over time and age. All regions had a significant 
interaction of group by time. (a) Brainstem, (b) Ventral pons, (c) Cerebellar white matter, (d) Cerebellar 
gray matter, and (e) Thalamus. Freesurfer-derived volume is on the Y-axis and age is on the X-axis. Markers 
connected by a line denote age at each session for an individual over time. Open markers represent controls 
while solid markers represent Wolfram participants.
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development (axonal and neuronal degeneration). In addition, abnormal trajectories were found preferentially 
in the brainstem, cerebellum, thalamus and the white matter tracts that connect them while most of higher order 
cortex followed normal developmental trends in Wolfram syndrome. Finally, our findings suggest that thalamic 
volume is a novel and potentially useful biomarker for neurodegeneration in Wolfram syndrome, with the sta-
tistical power appropriate for small clinical trials. Together, these results suggest regionally specific neurodevel-
opmental and neurodegenerative processes at work that ultimately may explain the trajectory of neurological 
symptoms and provide data highly relevant to ongoing and future clinical trials in Wolfram syndrome.
Normal neurodevelopment, as reflected by tissue volume, is dynamic and multifactorial. In general, from 
childhood to early adulthood, white matter volume increases linearly, likely due to ongoing myelination of axons. 
In contrast, cortical gray matter volume peaks at an early age and then decreases over development, likely due to 
synapse elimination and dendritic pruning41–44. These processes also differ regionally, with higher order cortical 
regions developing later than primary sensory areas43–46. For example, primary visual and motor cortex reaches 
peak thickness around age 8, whereas prefrontal cortical gray matter reaches peak thickness around age 11, after 
which they decline to adulthood in a fairly linear manner47. Volumes for subcortical regions peak at about 13–19 
years of age48 but the rate of increases and decreases are much more muted than for cortical gray matter44,49. 
Volumetric results from our control group recapitulated these known patterns in this age range, demonstrating 
Figure 4. Mean (±SEM) estimated annual percent rate of change for regions of interest. Each individual’s 
estimated slopes from the mixed model analysis were scaled by their average volumes to calculate annual 
percent change for each region. Mean annual percent change for each region across groups is shown with the 
control group on the left and the Wolfram group on the right. Error bars represent standard error of the mean. 
*p < 0.05, one tailed t-test vs. 0.
Figure 5. Correlation between percent change in thalamic volume and WURS physical score in Wolfram 
participants. Greater physical symptom severity (higher WURS score) at enrollment was associated with greater 
negative change in thalamic volume over time (rs = −0.669, p = 0.003, n = 17).
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mostly increasing volume in white matter, decreasing volume in cortical gray matter and relatively stable volume 
in subcortical gray matter. The complexities of these normal trajectories are an important backdrop for under-
standing the specific impact of Wolfram syndrome on the brain.
Over time, brain volumes in Wolfram syndrome appear to deviate from normal trajectories in a region and 
tissue-specific manner. Interestingly, we found no significant interactions with age, suggesting that group dif-
ferences in trajectories are not dependent on the age of the individual. This result could mean that other factors 
are more powerful in driving individual differences in neurodegenerative processes in Wolfram than just age 
(e.g. severity of mutation) or that our sample is not large or diverse enough in age to be able to detect a 3-way 
interaction.
In white matter regions that increase in volume across normal development, the Wolfram group had stable 
(optic radiations, frontal white matter) or decreasing volume (cerebellar white matter, brainstem, pons). These 
findings suggest that Wolfram syndrome may interfere with the ability to myelinate existing axons over age and, 
in some regions, cause damage to myelin and/or axons. In addition, we observed lower white matter volumes 
at very early ages (e.g. 5), which may suggest an early lack of myelin and/or axonal development. Our previous 
cross-sectional diffusion tensor imaging (DTI) analyses were consistent with hypomyelination24, but longitudinal 
DTI analysis could help determine the impact of Wolfram syndrome on myelin vs. axons over time. It is possible 
that, as in other demyelinating diseases (e.g. multiple sclerosis50), lack of myelination precedes axonal damage, 
axonal loss and finally neuronal loss28. Longitudinal DTI analyses that may allow for these more detailed neuro-
biological interpretations are underway but outside the scope of this paper.
In gray matter regions that decrease in volume over this age range (cortex, cerebellum), the Wolfram group 
demonstrated a relatively normal trajectory of decreasing volume (cortex), except for a very small part of visual 
cortex and cerebellar cortex, which appeared to have accelerated decreases in volume. In normal development, 
decreased gray matter volume is thought to reflect synaptic and dendritic pruning51. Thus, it may be that Wolfram 
syndrome is associated with accelerated or excessive pruning or cell death in these restricted areas. In gray matter 
that is relatively stable over this age range (subcortex)46, the Wolfram group demonstrated an abnormal decrease 
in thalamic volume, but no differences in the other regions. We hypothesize that this pattern is most consistent 
with neuronal loss, perhaps due to loss or dysfunction of axons that project to or from thalamic nuclei as seen 
in other neurodegenerative diseases52. Interestingly, the voxel-wise findings appeared predominantly within the 
posterior thalami, which is composed of nuclei with inputs and outputs to the visual system, including pulvi-
nar, lateral posterior and lateral geniculate nuclei53. Segmentation of thalamic nuclei might help us understand 
structure-function relationships and improve its use as a biomarker of neurodegeneration54. Further, rate of 
change in thalamic volume was predicted by disease severity (WURS Physical score) at time 1, suggesting that 
thalamic neuronal loss may be a later appearing sign in Wolfram syndrome, and have some clinical relevance. We 
determined that to detect a 50% slowing of thalamic volume loss, a clinical trial would require 34 patients per arm 
(treatment vs placebo) to achieve power of >0.80, which would be feasible even for an ultra-rare disease such as 
Wolfram syndrome.
Neuropathological studies of individuals with Wolfram syndrome are rare and findings have been somewhat 
variable. However, if these cases are arranged according to the age and severity of the patient, there does appear to 
be some support for an evolution of neuropathological findings from restricted myelin and axonal loss to wide-
spread myelin, axonal and neuronal loss. Neuropathological examination of a 15 year old who died accidentally 
revealed reduced myelin and axons in restricted areas and neuronal loss only in the hypothalamus11. Exam results 
from a 21 year old with more extensive symptoms were similar but also included myelin and axon loss in the optic 
radiations and diffuse demyelination throughout the rest of the brain11. A 24 year old with advanced neurological 
symptoms at the time of death had widespread axonal loss and neuronal death10. Similarly, a 36 year old with 
severe neurologic symptoms at time of death had severe loss of myelin and presence of gliosis in the optic nerves 
and loss of myelin and neurons in the cerebellum55. Finally, a 38 year old patient with advanced symptoms at the 
time of death had axonal swelling and dystrophy, neuronal loss and gliosis in brainstem, cerebellum and optic 
nerves, and also neuronal loss and gliosis in thalamus56. Of note, these cases were all published before the age 
of genetic confirmation for Wolfram syndrome, used different methods and in some cases did not examine the 
entire brain, and so need to be viewed with some caution. Despite these caveats, it appears that cases with greater 
symptom severity may have more widespread axonal and neuronal pathology.
The functional consequences of these neurodevelopmental and neurodegenerative changes in Wolfram syn-
drome are unclear. However, we can speculate that white matter loss in the brainstem and pons could affect a 
wide range of motor, sensory and other essential functions (e.g. respiration, urination) known to be affected 
in Wolfram syndrome. In fact, in a cross-sectional, correlational analysis, we found that ventral pons volume 
correlated with the degree of urinary dysfunction30. In addition, gait and balance, which are associated with the 
cerebellum, are known to be abnormal in Wolfram syndrome, even at the early stages of the disease process7,8. 
Ultimately, we hope to understand whether change in neurological symptoms over time can be predicted by 
regional brain morphometry. Such information could strengthen the clinical relevance of these measures as out-
comes for clinical trials, and lead to a better understanding of the key neuropathological changes in Wolfram 
syndrome that deserve further attention.
The major strength of this study is the longitudinal quantification of structural brain abnormalities in 
Wolfram syndrome compared to well-matched controls using voxel-wise and regional approaches. However, 
there are some limitations to our study. First, although all Wolfram group members who were willing to travel to 
St. Louis were accepted into the study, this requirement may have selected for individuals who were less severely 
affected than the general Wolfram syndrome population. Second, the maximum number of years that the control 
group was followed was shorter (n = 3) than for the Wolfram group (n = 7). Fortunately, mixed model statistical 
approaches are designed to handle this difference. In addition our primary results were quite robust and patterns 
can be seen clearly at the raw data level. Finally, the scope of this paper included longitudinal volumetric change 
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in Wolfram syndrome. Future analyses will need to address longitudinal change in diffusion weighted imaging 
and behavior. We ultimately hope to determine whether rates of change in specific symptoms correlates with rate 
of change in specific brain regions or tissue types.
Our unique longitudinal neuroimaging dataset in Wolfram syndrome clearly indicate that while some 
morphometric brain abnormalities are present very early in the disease course, others appear to increase over 
time. The patterns observed suggest that both altered neurodevelopmental and degenerative processes occur in 
Wolfram syndrome distributed across region and tissue type. Animal models of Wolfram syndrome are improv-
ing57, with recent papers suggesting gross neurologic alterations that resemble the basic cross-sectional differ-
ences seen in human neuroimaging. The challenge remains to verify in animal models the longitudinal patterns 
seen here in our analyses and to determine whether there is a unifying primary mechanism that can explain both 
the spatial and tissue-specific patterns. Furthermore, understanding the predictive value of gene mutation for rate 
of progression of neurologic symptoms and brain degeneration is a future goal requiring larger samples. These 
issues have been explored in the past using retrospectively acquired basic clinical information (e.g. reported age 
of onset of symptoms)6,58. Future work will need to examine genotype-phenotype relationships using objective, 
quantified and longitudinal neuroimaging metrics, as presented in this paper, with a larger and more diverse 
sample.
Data Availability
The raw data used in the analyses described in this manuscript cannot be made available in the manuscript, sup-
plemental files, or a public repository because the sample size of our Wolfram syndrome patient group is so small, 
and the disease so rare, that human participant characteristics such as sex, age, and number of visits could be 
used to identify individuals even after de-identification of the data. The corresponding author, Dr. Hershey, may 
be contacted to request data. As per the Human Research Protection Office (HRPO) at Washington University, a 
preface to data sharing agreement and a data sharing agreement reviewed by the research office will be employed 
prior to data sharing. HRPO regulations permit access to potentially identifiable data only to research personnel 
on our study protocol and approved through the University.
References
 1. Minton, J. A. L., Rainbow, L. A., Ricketts, C. & Barrett, T. G. Wolfram syndrome. Reviews in Endocrine & Metabolic Disorders 4, 
53–59 (2003).
 2. Barrett, T. G., Bundey, S. E. & Macleod, A. F. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) 
syndrome. Lancet 346, 1458–1463 (1995).
 3. Inoue, H. et al. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram 
syndrome). Nat. Genet 20, 143–148 (1998).
 4. Chaussenot, A. et al. Neurologic features and genotype-phenotype correlation in wolfram syndrome. Ann. Neurol (2010).
 5. Marshall, B. A. et al. Phenotypic characteristics of early Wolfram syndrome. Orphanet. J Rare. Dis 8, 64, https://doi.org/10.1186/1750-
1172-8-64 (2013).
 6. de Heredia, M. L., Cleries, R. & Nunes, V. Genotypic classification of patients with Wolfram syndrome: insights into the natural 
history of the disease and correlation with phenotype. Genet Med 15, 497–506 (2013).
 7. Pickett, K. A. et al. Early presentation of gait impairment in Wolfram Syndrome. Orphanet. J Rare. Dis 7, 92, https://doi.
org/10.1186/1750-1172-7-92 (2012).
 8. Pickett, K. A. et al. Balance impairment in individuals with Wolfram syndrome. Gait. Posture 36, 619–624 (2012).
 9. Hershey, T. et al. Early brain vulnerability in Wolfram syndrome. Plos. One 7, e40604, https://doi.org/10.1371/journal.pone.0040604 
(2012).
 10. Hilson, J. B., Merchant, S. N., Adams, J. C. & Joseph, J. T. Wolfram syndrome: a clinicopathologic correlation. Acta Neuropathologica 
118, 415–428 (2009).
 11. Carson, M. J., Slager, U. T. & Steinberg, R. M. Simultaneous occurrence of diabetes mellitus, diabetes insipidus, and optic atrophy in 
a brother and sister. Am. J. Dis. Child 131, 1382–1385 (1977).
 12. Khardori, R., Stephens, J. W., Page, O. C. & Dow, R. S. Diabetes-Mellitus and Optic Atrophy in 2 Siblings - A Report on A New 
Association and A Review of the Literature. Diabetes Care 6, 67–70 (1983).
 13. Gregorios, J. B. Wolframs Syndrome with Schizophrenia and Central Hypoventilation - A Neuropathological Study. Journal of 
Neuropathology and Experimental Neurology 48, 308–308 (1989).
 14. Genis, D., Davalos, A., Molins, A. & Ferrer, I. Wolfram syndrome: A neuropathological study. Acta Neuropathologica 93, 426–429 
(1997).
 15. Takeda, K. et al. WFS1 (Wolfram syndrome 1) gene product: predominant subcellular localization to endoplasmic reticulum in 
cultured cells and neuronal expression in rat brain. Human Molecular Genetics 10, 477–484 (2001).
 16. Ishihara, H. et al. Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling 
in insulin secretion. Hum. Mol. Genet 13, 1159–1170 (2004).
 17. Fonseca, S. G., Burcin, M., Gromada, J. & Urano, F. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr. 
Opin. Pharmacol 9, 763–770 (2009).
 18. Fonseca, S. G. et al. WFS1 is a novel component of the unfolded protein response and maintains homeostasis of the endoplasmic 
reticulum in pancreatic beta-cells. J. Biol. Chem 280, 39609–39615 (2005).
 19. Fonseca, S. G. et al. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 120, 
744–755 (2010).
 20. Riggs, A. C. et al. Mice conditionally lacking the Wolfram gene in pancreatic islet beta cells exhibit diabetes as a result of enhanced 
endoplasmic reticulum stress and apoptosis. Diabetologia 48, 2313–2321 (2005).
 21. Yamada, T. et al. WFS1-deficiency increases endoplasmic reticulum stress, impairs cell cycle progression and triggers the apoptotic 
pathway specifically in pancreatic beta-cells. Hum. Mol. Genet 15, 1600–1609 (2006).
 22. Akiyama, M. et al. Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout 
mice. Diabetologia 52, 653–663 (2009).
 23. Lu, S. et al. A calcium-dependent protease as a potential therapeutic target for Wolfram syndrome. Proc. Natl. Acad. Sci. USA 111, 
E5292–E5301, https://doi.org/10.1073/pnas.1421055111 (2014).
 24. Lugar, H. M. et al. Neuroimaging evidence of deficient axon myelination in Wolfram syndrome. Sci Rep 6, 21167, https://doi.
org/10.1038/srep21167 (2016).
1 0Scientific RepoRts |          (2019) 9:6010  | https://doi.org/10.1038/s41598-019-42447-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
 25. Bischoff, A. N. et al. Selective cognitive and psychiatric manifestations in Wolfram Syndrome. Orphanet. J Rare. Dis 10, 66, https://
doi.org/10.1186/s13023-015-0282-1 (2015).
 26. Nguyen, C. et al. Reliability and validity of the Wolfram Unified Rating Scale (WURS). Orphanet. J Rare. Dis 7, 89, https://doi.
org/10.1186/1750-1172-7-89 (2012).
 27. Hoekel, J., Chisholm, S. A., Al-Lozi, A., Hershey, T. & Tychsen, L. Ophthalmologic correlates of disease severity in children and 
adolescents with Wolfram syndrome. J Aapos 18, 461–465 (2014).
 28. Karzon, R. K. & Hullar, T. E. Audiologic and vestibular findings in Wolfram syndrome. Ear Hear 34, 809–812 (2013).
 29. Karzon, R., Narayanan, A., Chen, L., Lieu, J. E. C. & Hershey, T. Longitudinal hearing loss in Wolfram syndrome. Orphanet J Rare 
Dis 13, 102, https://doi.org/10.1186/s13023-018-0852-0 (2018).
 30. Rove, K. O. et al. Lower Urinary Tract Dysfunction and Associated Pons Volume in Patients with Wolfram Syndrome. J Urol 200, 
1107–1113 (2018).
 31. Bumpus, E. et al. Understanding activity participation among individuals with Wolfram Syndrome. Br J Occup Ther 81, 348–357 
(2018).
 32. Hoekel, J. et al. Visual pathway function and structure in Wolfram syndrome: patient age, variation and progression. BMJ Open 
Ophthalmol 3, e000081, https://doi.org/10.1136/bmjophth-2017-000081 (2018).
 33. Doty, T., Foster, E. R., Marshall, B., Ranck, S. & Hershey, T. The effects of disease-related symptoms on daily function in Wolfram 
Syndrome. Transl Sci Rare Dis 2, 89–100 (2017).
 34. Astuti, D. et al. Monogenic diabetes syndromes: Locus-specific databases for Alstrom, Wolfram, and Thiamine-responsive 
megaloblastic anemia. Hum Mutat 38, 764–777 (2017).
 35. Ashburner, J. & Ridgway, G. R. Symmetric diffeomorphic modeling of longitudinal structural MRI. Front Neurosci 6, 197, https://
doi.org/10.3389/fnins.2012.00197 (2012).
 36. Ashburner, J. & Friston, K. J. Unified segmentation. Neuroimage 26, 839–851 (2005).
 37. Ashburner, J. A fast diffeomorphic image registration algorithm. Neuroimage 38, 95–113 (2007).
 38. Guillaume, B. et al. Fast and accurate modelling of longitudinal and repeated measures neuroimaging data. Neuroimage 94, 287–302 
(2014).
 39. Buckner, R. L. et al. A unified approach for morphometric and functional data analysis in young, old, and demented adults using 
automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. 
Neuroimage 23, 724–738 (2004).
 40. Fischl, B. et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 33, 
341–355 (2002).
 41. Dennis, E. L. & Thompson, P. M. Typical and atypical brain development: a review of neuroimaging studies. Dialogues Clin Neurosci 
15, 359–384 (2013).
 42. Hua, X. et al. Detecting brain growth patterns in normal children using tensor-based morphometry. Hum Brain Mapp 30, 209–219 
(2009).
 43. Thompson, P. M. et al. Structural MRI and Brain Development. Int Rev Neurobiol 67, 285–323 (2005).
 44. Ostby, Y. et al. Heterogeneity in subcortical brain development: A structural magnetic resonance imaging study of brain maturation 
from 8 to 30 years. J Neurosci 29, 11772–11782 (2009).
 45. Giedd, J. N. & Rapoport, J. L. Structural MRI of pediatric brain development: what have we learned and where are we going? Neuron 
67, 728–734 (2010).
 46. Giedd, J. N. et al. Child psychiatry branch of the National Institute of Mental Health longitudinal structural magnetic resonance 
imaging study of human brain development. Neuropsychopharmacology 40, 43–49 (2015).
 47. Shaw, P. et al. Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci 28, 3586–3594 (2008).
 48. Wierenga, L. et al. Typical development of basal ganglia, hippocampus, amygdala and cerebellum from age 7 to 24. Neuroimage 96, 
67–72 (2014).
 49. Wierenga, L. M., Langen, M., Oranje, B. & Durston, S. Unique developmental trajectories of cortical thickness and surface area. 
Neuroimage 87, 120–126 (2014).
 50. Siffrin, V., Vogt, J., Radbruch, H., Nitsch, R. & Zipp, F. Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends 
Neurosci 33, 202–210 (2010).
 51. Gogtay, N. et al. Dynamic mapping of human cortical development during childhood through early adulthood. Proc. Natl. Acad. Sci 
USA 101, 8174–8179 (2004).
 52. Power, B. D. & Looi, J. C. The thalamus as a putative biomarker in neurodegenerative disorders. Aust N Z J Psychiatry 49, 502–518 
(2015).
 53. Benarroch, E. E. Pulvinar: associative role in cortical function and clinical correlations. Neurology 84, 738–747 (2015).
 54. Battistella, G. et al. Robust thalamic nuclei segmentation method based on local diffusion magnetic resonance properties. Brain 
Struct Funct 222, 2203–2216 (2017).
 55. Jackson, M. J. et al. Biochemical and Molecular Studies of Mitochondrial-Function in Diabetes-Insipidus, Diabetes-Mellitus, Optic 
Atrophy, and Deafness. Diabetes Care 17, 728–733 (1994).
 56. Shannon, P., Becker, L. & Deck, J. Evidence of widespread axonal pathology in Wolfram syndrome. Acta Neuropathologica 98, 
304–308 (1999).
 57. Plaas, M. et al. Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve 
atrophy and medullary degeneration. Sci Rep 7, 10220, https://doi.org/10.1038/s41598-017-09392-x (2017).
 58. Chaussenot, A. et al. Neurologic features and genotype-phenotype correlation in Wolfram syndrome. Ann Neurol 69, 501–508 
(2011).
Acknowledgements
We thank all of the participants and their families for their time and effort, and the study staff for their dedication. 
Research reported in this publication was supported by HD070855 (Hershey, PI), U54 HD087011 (Intellectual 
and Developmental Disabilities Research Center at Washington University), UL1 RR024992 (CTSA), DK020579 
(Diabetes Research Center), The Snow Foundation, American Diabetes Association, George Decker and Julio 
V. Santiago Pediatric Diabetes Research Fund, Mallinckrodt Institute of Radiology and the McDonnell Center 
for Systems Neuroscience. We thank the former and current Washington University Wolfram Study Group 
Members for advice and support in the greater research program: P. Austin, MD (Surgery), B. Beato, BA 
(Psychiatry), E. Bihun, MA (Psychiatry), A. Bischoff, BA (Psychiatry), T. Doty, MA (Occupational Therapy), 
G. Earhart, PhD (Physical Therapy), S. Eisenstein, PhD (Psychiatry), T. Hershey, PhD (Psychiatry), J. Hoekel, 
DO (Ophthalmology), R. Karzon, PhD (Audiology & Comm. Sciences), J. Koller BSBME (Psychiatry), A. Licis, 
MD (Neurology), H. Lugar, MS (Psychiatry), L. Manwaring, MS (Pediatrics), B. Marshall, MD (Pediatrics), 
A. Narayanan, BA (Psychiatry), O. Neyman, BME (Psychiatry), A.R. Paciorkowski, MD (Neurology, URMC), 
T. Pearson, MD (Neurology), Y. Pepino de Gruev, PhD (University of Illinois), A. Permutt, MD (Medicine) 
1 1Scientific RepoRts |          (2019) 9:6010  | https://doi.org/10.1038/s41598-019-42447-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
(Deceased), K. Pickett, PhD (Physical Therapy, U Wisconsin), S. Ranck, MSW (Psychiatry), A. Reiersen, MD 
(Psychiatry), J. Rutlin, BS (Psychiatry), J. Shimony, MD, PhD (Radiology), L. Tychsen, MD (Ophthalmology), F. 
Urano MD, PhD (Medicine), A. Viehoever, MD (Neurology), J. Wasson, MS (Medicine) (Deceased), N.H. White 
MD, CDE (Pediatrics).
Author Contributions
All authors were involved in the conception/design of the study and the named authors read, reviewed and 
approved the manuscript. In addition, HML collected Wolfram and control data, analyzed and helped interpret 
data, prepared figures and tables, and wrote and edited the manuscript. J.R. and A.N. collected Wolfram and 
control data. J.R. and J.M.K. analyzed data. J.M.K. helped interpret data and prepare figures, and edited the 
manuscript. S.A.E., O.N., A.N. and J.S.S. assisted in analysis and interpretation of the data. L.C. performed 
statistical analyses and interpreted data. T.H. designed the study, supervised the research, performed data 
analysis, and wrote and edited the manuscript.
Additional Information
Competing Interests: The authors declare no competing interests.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2019
